Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: Beginning of epidemic control

THORNTON, V; Lennon, Diana; Rasanathan, Kumanan; O’Hallahan, Jane; Oster, Philipp; Stewart, Joanna; Tilman, Sandrine; Aaberge, Ingeborg S.; Feiring, Berit; Nøkleby, Hanne

doi:10.1016/j.vaccine.2005.09.043

Cited by 57 publications

(52 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[9][10][11][12] We found ethnicity and vaccine administrator to be significantly associated with both perceived pain on injection and reported injection site reactions.…”

Section: Discussionmentioning

confidence: 75%

“…[9][10][11]17 Limitations of study One of the limitations of the MeNZB TM vaccine data is the way ethnicity data were requested. The demographic questionnaire did not seek ethnicity information in a way that was consistent with Statistics NZ nor the Ministry of Health.…”

Section: Strengths Of Studymentioning

confidence: 99%

“…The outer membrane vesicles were extracted using the detergent deoxycholate, separated by centrifugation and then adsorbed to aluminum hydroxide. 10 Each 0.5 mL vaccine dose contained 25 mg total protein and 1.65 mg aluminum hydroxide. Children from cohort A received MeNZB TM vaccine manufactured in a single batch by the Norwegian Institute of Public Health (NIPH), Oslo, Norway or the Norwegian parent vaccine.…”

Section: Populationmentioning

confidence: 99%

See 2 more Smart Citations

Factors associated with reported pain on injection and reactogenicity to an OMV meningococcal B vaccine in children and adolescents

Petousis‐Harris

Jackson

Stewart

et al. 2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Pain on vaccine injection and subsequent site reactions of pain and swelling may influence confidence in vaccines and their uptake. This study aimed to identify factors associated with reported pain on injection and reactogenicity following administration of a strain specific meningococcal B outer membrane vesicle vaccine. A retrospective analysis of data was conducted from a phase II single center randomized observer-blind study that evaluated the safety, reactogenicity and immunogenicity of this vaccine in 2 cohorts of healthy 8 to 12 y old children. Vaccine administration technique was observed by an unblinded team member and the vaccine administrator instructed on standardized administration. Participants kept a daily diary to record local reactions (erythema, induration and swelling) and pain for 7 d following receipt of the vaccine. Explanatory variables were cohort, vaccine, age, gender, ethnicity, body mass index, atopic history, history of frequent infections, history of drug reactions, pain on injection, vaccinator, school population socioeconomic status, serum bactericidal antibody titer against the vaccine strain NZ98/254, and total IgG. Univariate and multivariable analyses were conducted using ordinal logistic regression for factors relating to pain on injection and reactogenicity. Perceived pain on injection was related to vaccine formulation, vaccine administrator and ethnicity. Reactogenicity outcomes varied with ethnicity and vaccine administrator. Maintaining community and parental confidence in vaccine safety without drawing attention to differences between individuals and groups is likely to become increasingly difficult. Vaccine administration technique alone has the potential to significantly reduce pain experienced on injection and local vaccine reactions.

show abstract

“…[9][10][11][12] We found ethnicity and vaccine administrator to be significantly associated with both perceived pain on injection and reported injection site reactions.…”

Section: Discussionmentioning

confidence: 75%

Section: Strengths Of Studymentioning

confidence: 99%

Section: Populationmentioning

confidence: 99%

See 1 more Smart Citation

Factors associated with reported pain on injection and reactogenicity to an OMV meningococcal B vaccine in children and adolescents

Petousis‐Harris

Jackson

Stewart

et al. 2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…Vaccines to confer protection against serogroup B disease developed from N. meningitidis OMVs have been assessed in efficacy trials conducted in Cuba, 6 Brazil 7 and Norway 8 and are currently in use in New Zealand to control an epidemic of serogroup B disease. 9 OMV vaccines are complex and contain multiple immunogenic proteins, many of which are known to be highly variable. One of the most immunogenic components of meningococcal OMV vaccines is the PorA surface porin and antigenic variation of this protein has been well documented.…”

Section: Introductionmentioning

confidence: 99%

Characterization of the key antigenic components and pre-clinical immune responses to a meningococcal disease vaccine based onNeisseria lactamicaouter membrane vesicles

Finney¹,

Vaughan²,

Taylor³

et al. 2008

Human Vaccines

View full text Add to dashboard Cite

“…In the first of the clinical trials undertaken with adults, the safety and immunogenicity of MeNZB after three doses were compared with those of the parent vaccine, MenBvac (50). The present study describes the vaccine-induced responses to both vaccines in this trial, in which a larger set of immunological assays was applied.…”

mentioning

confidence: 99%

Functional and Specific Antibody Responses in Adult Volunteers in New Zealand Who Were Given One of Two Different Meningococcal Serogroup B Outer Membrane Vesicle Vaccines

Wedege

Bolstad

Aase

et al. 2007

Clin Vaccine Immunol

View full text Add to dashboard Cite

Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: Beginning of epidemic control

Cited by 57 publications

References 20 publications

Factors associated with reported pain on injection and reactogenicity to an OMV meningococcal B vaccine in children and adolescents

Factors associated with reported pain on injection and reactogenicity to an OMV meningococcal B vaccine in children and adolescents

Characterization of the key antigenic components and pre-clinical immune responses to a meningococcal disease vaccine based onNeisseria lactamicaouter membrane vesicles

Functional and Specific Antibody Responses in Adult Volunteers in New Zealand Who Were Given One of Two Different Meningococcal Serogroup B Outer Membrane Vesicle Vaccines

Contact Info

Product

Resources

About